Advancing a class on top of statins
Investors & Media

Investor Overview

Webcast ImageGemphire Therapeutics, Inc. at H.C. Wainwright 2nd Annual NASH Investor Conference (Replay)03/19/18 at 8:40 a.m. ET

Gemphire Therapeutics, Inc. at H.C. Wainwright 2nd Annual NASH Investor Conference
Monday, March 19, 2018 8:40 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease. Dyslipidemia is generally characterized by an elevation of low-density lipoprotein cholesterol (LDL-C), or bad cholesterol, triglycerides, or fat in the blood, or both... More >>

NASDAQ | GEMP (Common Stock)


0.00 (0.00%)

Market Cap$97,533,372

03/20/18  4:00 p.m. ET

Data provided by Nasdaq. Minimum 15 minutes delayed.
Stock chart for: GEMP.O.  Currently trading at $7.08 with a 52 week high of $21.59 and a 52 week low of $6.07.

Gemphire Therapeutics Reports Fourth Quarter and Fiscal Year 2017 Financial Results


Read More

Gemphire Therapeutics to Announce Fourth Quarter and Year End 2017 Financial Results on Thursday, March 15


Read More

Gemphire to Present at Two Investor Conferences


Read More

There are currently no events scheduled.